Skip to main content

Provincial Retinal Diseases Treatment Program

The Provincial Retinal Diseases Treatment
Program provides drug treatment therapy for B.C. patients diagnosed with wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion.

The Provincial Retinal Diseases Treatment Program (PRDTP) was established in June 2009 to plan, coordinate, monitor, evaluate and fund retinal disease treatments. The program provides 100% coverage for a number of drugs for the treatment of retinal diseases when the drugs are prescribed and administered by retinal specialists.

PHSA manages the provincial program on behalf of the Ministry of Health by:
  • monitoring regional access to care,
  • optimizing drug utilization appropriateness and cost control,
  • minimizing drug wastage, and
  • facilitating data collection, monitoring, measuring, and reporting.
The standard of care for the treatment of retinal diseases is anti-vascular endothelial growth factor (anti-VEGF) drugs. These medications have been shown to help prevent vision loss and/or blindness, particularly in seniors.
Our work

How we serve the people of B.C.

Through the provincial program, B.C. patients have access to anti-VEGF drugs when they have been diagnosed with one of the following three conditions:

wAMD is a chronic eye disease that causes blurred vision or a blind spot in your visual field. It’s generally caused by abnormal blood vessels that leak fluid or blood into the macula. The macula is in the part of the retina responsible for central vision. Early detection and treatment of macular degeneration may help reduce vision loss and, in some instances, recover vision.

DME is an accumulation of fluid in the macula from leaking blood vessels. To develop DME, you must first have diabetic retinopathy. Diabetic retinopathy is a disease that damages the blood vessels in the retina, resulting in vision impairment.

 

RVO is a blockage of the veins in the retina that carry blood away from the eye. The blockage can cause fluid to leak into the macula. The blockage caused by RVO cannot be reversed, but there are ways in which it can be managed, using treatments that may slow down the progression of vision loss and even improve vision.

 
B.C. patients who have been diagnosed with one of the above conditions have access to the following anti-VEGF drugs:
  • bevacizumab (Avastin)
  • ranibizumab (Lucentis)
  • aflibercept (Eylea)
This program also provides coverage for verteporfin (Visudyne) with photodynamic therapy for wet age-related macular degeneration (wAMD).

New patients can access the treatments through a referral from a physician or optometrist to a retinal specialist. Retinal specialist services are available in all regional health authorities. Patients are urged to talk with the retinal specialist regarding the benefits and risks of the treatments.

Key partnerships

The 29 retinal specialists participating in the Provincial Retinal Diseases Treatment Program collaborate with PHSA and the Ministry of Health to ensure the planning, coordination, accessibility, quality, efficiency, and effectiveness of the provincial program.
Quality Improvement

Program quality improvement

 
  • The Phase IV quality working group (QWG) has now come together.
  • The roles and responsibilities of the QWG were reviewed.
  • The supportive structures for this work were reviewed and include the QWG, an analytics sub-group who include additional biostatisticians and epidemiologists and who will complete work on analyses between meetings of the QWG, and external experts (out of province) who will provide review and advice regarding analytical procedures and results.
  • The draft preliminary study questions were reviewed and agreed upon.
  • Work done to date was highlighted. After reviewing the data extract, data intake and cleaning was undertaken. Initial linkage of the datasets occurred. Descriptive review of the data including preparing the data sets for analyses was completed.
  • The analytics sub-group will begin more frequent meetings to undertake analyses based on today’s agreed upon questions to bring back to the QWG in four weeks’ time.
  • Next QWG meeting scheduled for November 22, 2019.

Tab Heading
Tab Heading
SOURCE: Provincial Retinal Diseases Treatment Program ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © Provincial Health Services Authority. All Rights Reserved.

    Copyright © 2021 Provincial Health Services Authority